Heron Therapeutics Inc. (HRTX)

[barefootrunner]

Whether right or wrong, you are correct in that this is how the market is looking upon APPA - i.e. both delayed and acute is where the real market potential is. Just acute means they will just be another player in an already established market that is currently dominated by Aloxi.

I agree the Phase III data is promising for both, but you simply never know with the FDA. Depends on whether they use superiority or non-inferiority as the criteria to approve APF530 for delyed CINV. Another posted shared data last week that seemed to indicate that the FDA leans toward non-inferiority as opposed to superiority, but I have not had time to research this historically.